Volume 23, Issue 12 pp. 1131-1138
Original Article

Effect of haemodialysis and residual renal function on serum levels of galectin-3, B-type natriuretic peptides and cardiac troponin T

Matthew A Roberts

Corresponding Author

Matthew A Roberts

Department of Nephrology, Austin Health, Heidelberg, Victoria, Australia

Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

Correspondence:

Dr Matthew Roberts, Eastern Health Clinical School, Monash University, Level 2, 5 Arnold Street, Box Hill, Vic. 3128, Australia. Email: [email protected]

Search for more papers by this author
Piyush M Srivastava

Piyush M Srivastava

Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

Department of Cardiology, Austin Health, Heidelberg, Victoria, Australia

Search for more papers by this author
David L Hare

David L Hare

Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

Department of Cardiology, Austin Health, Heidelberg, Victoria, Australia

Search for more papers by this author
Francesco L Ierino

Francesco L Ierino

Department of Nephrology, Austin Health, Heidelberg, Victoria, Australia

Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

Search for more papers by this author
First published: 13 October 2017
Citations: 5
Present address: Assistant Professor Matthew A Roberts PhD, Eastern Health Clinical School, Monash University, Victoria, Australia.
Present address: Professor Francesco L Ierino MD, PhD, FRACP, Department of Nephrology, St Vincent's Health, Fitzroy, Victoria, Australia.

ABSTRACT

Aim

Levels of plasma markers of myocardial fibrosis (galectin-3), stretch (B-type natriuretic peptide (BNP)) and injury (high-sensitivity troponin T (hs-TnT)) are affected by haemodialysis, residual renal function (RRF) and cardiac pathology. We aimed to determine the association of RRF, urine output and haemodialysis itself on cardiac biomarkers in haemodialysis patients.

Methods

Adult haemodialysis patients underwent venesection pre- and post-haemodialysis then echocardiography and inter-dialytic urine collection to calculate RRF (mL/min per 1.73m2) and urine output (mL/day). Galectin-3, BNP-32, NT-ProBNP and hs-TnT levels were compared across tertiles of echocardiographic parameters, RRF and urine output using the non-parametric test for trend across ordered groups.

Results

Twenty-three patients (17 male) with mean age 67.7±13.8 years and median (interquartile range) dialysis duration 13.6 (9.8–19.1) months participated. Galectin-3 was substantially lower following haemodialysis: 55 ng/mL (47–70) versus 23 ng/mL (19–27, P < 0.001), but other biomarkers changed little. By increasing RRF tertile, post-dialysis galectin-3 was 32.6 ng/mL (23.7–36.6), 21.9 ng/mL (19.0–23.2) and 19.0 ng/mL (16.9–21.0, P = 0.001); NT-ProBNP was 10 192 ng/L (2303–21 504), 2037 ng/L (1224–10 795) and 1481 ng/L (172–2890, P = 0.016). Results were similar for daily urine volume, but measured echocardiographic parameters were not associated with biomarker concentrations.

Conclusion

Plasma concentration of galectin-3 is reduced by the haemodialysis procedure. Lower RRF and urine volume are strongly associated with higher levels of galectin-3 and NT-Pro-BNP. These associations are important to the clinical interpretation of these biomarker levels in haemodialysis patients.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.